These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 26088100)
1. Functions of Shp2 in cancer. Zhang J; Zhang F; Niu R J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100 [TBL] [Abstract][Full Text] [Related]
2. [The Biological Function of SHP2 in Human Disease]. Li SM Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808 [TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227 [TBL] [Abstract][Full Text] [Related]
4. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348 [TBL] [Abstract][Full Text] [Related]
5. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959 [TBL] [Abstract][Full Text] [Related]
7. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822 [TBL] [Abstract][Full Text] [Related]
8. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling. Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426 [TBL] [Abstract][Full Text] [Related]
9. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer. Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342 [TBL] [Abstract][Full Text] [Related]
10. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Chan G; Kalaitzidis D; Neel BG Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234 [TBL] [Abstract][Full Text] [Related]
12. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810 [TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780 [TBL] [Abstract][Full Text] [Related]
15. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576 [TBL] [Abstract][Full Text] [Related]
16. SHP2 sails from physiology to pathology. Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048 [TBL] [Abstract][Full Text] [Related]
17. The tyrosine phosphatase Shp2 in development and cancer. Grossmann KS; Rosário M; Birchmeier C; Birchmeier W Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956 [TBL] [Abstract][Full Text] [Related]
18. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020). Wu J; Zhang H; Zhao G; Wang R Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341 [TBL] [Abstract][Full Text] [Related]
19. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990 [TBL] [Abstract][Full Text] [Related]
20. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]